KRAS and metastatic colorectal cancer: A recent meta-analysis reported that PIK3CA exon 20 mutations are associated with a significantly shorter DFS in KRAS wild-type metastatic colorectal cancer patients treated with anti-EGFR antibody cetuximab [35].